The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31456 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Dan Geller und 10 weiteren Autor:innen. Beteiligte Einrichtung: National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Monoclonal, Humanized, Antibodies, Bispecific, Hospitalization. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, NovoNordisk.
Abstract (Originalsprache)
Introduction
Hemophilia A (HA) therapy poses a significant healthcare burden. In recent years, emicizumab has been approved for prophylaxis. The current study explores the impact of transitioning to emicizumab on emergency department (ED) visits and hospitalizations in pediatric and adult HA patients.
Methods
Data of HA patients transitioned to emicizumab at the Israeli National Hemophilia Center was retrospectively analyzed. Demographic information, inhibitor status, treatment duration, number, and reasons of ED visits and hospitalizations were assessed.
Results
Overall, transitioning to emicizumab significantly reduced ED visits and hospitalizations. While children experienced a significant reduction in both ED visits and hospitalizations, adults showed no statistically significant change. Post‐emicizumab initiation, main reasons for ED visits among children shifted from prophylactic treatment and central line‐associated complications to injury‐related incidents.
Conclusions
This real‐world analysis demonstrates a substantial decrease in ED visits and hospitalizations, following emicizumab prophylaxis in HA patients. However, this improvement was age dependent as it was observed only among children. Further prospective studies evaluating this aspect may shed light on these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Hemophilia Center, Sheba Medical center, Tel Hashomer, Israel.
- Amalia Biron Research Institute of Thrombosis and Hemostasis, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
ORCID-Profile: Assaf A Barg
Förderung
- Pfizer
- NovoNordisk
Zitieren
APA
Geller, D., Budnik, I., Barhod, T., Cohen, O., Brutman-Barazani, T., Efros, O., Lubetsky, A., Lalezari, S., Levy-Mendelovich, S., Kenet, G., & Barg, A. A. (2025). The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31456
Vancouver
Geller D, Budnik I, Barhod T, Cohen O, Brutman-Barazani T, Efros O, et al. The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31456
BibTeX
@article{Geller2025,
author = {Geller, Dan and Budnik, Ivan and Barhod, Tlalit and Cohen, Omri and Brutman-Barazani, Tamar and Efros, Orly and Lubetsky, Aharon and Lalezari, Shadan and Levy-Mendelovich, Sarina and Kenet, Gili and Barg, Assaf A},
title = {The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31456}
}
EUVIMED